Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Iterum TherapeuticsITRMF EV-to-EBITDA is -0.98 as of Aug. 11, 2026. The stock has 4 warning signs investors should review. Among 402 Biotechnology companies, Iterum Therapeutics ranks worse than 248755.97% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Iterum Therapeutics's enterprise value is $22.73 Mil.
Iterum Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Sep. 2025 was $-23.20 Mil. Therefore, Iterum Therapeutics's EV-to-EBITDA for today is -0.98.
The historical rank and industry rank for Iterum Therapeutics's EV-to-EBITDA or its related term are showing as below:
ITRMF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -3.03 Med: -0.14 Max: 1.63
Current: -0.98
During the past 9 years, the highest EV-to-EBITDA of Iterum Therapeutics was 1.63. The lowest was -3.03. And the median was -0.14.
ITRMF's EV-to-EBITDA is ranked worse than 100% of 402
companies
in the Biotechnology industry
Industry Median: 13.3
vs ITRMF: -0.98
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Iterum Therapeutics (OTCPK:ITRMF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Iterum Therapeutics's PE Ratio (TTM) for today is calculated as:
Iterum Therapeutics's share price for today is $1.0E-5.
Iterum Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.750.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Iterum Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ITRMF vs HEPA, MTNB, VIVS: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Iterum Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Iterum Therapeutics EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Iterum Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Iterum Therapeutics's EV-to-EBITDA falls into.
Iterum Therapeutics's current Enterprise Value is $22.73 Mil.
Iterum Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-23.20 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Iterum Therapeutics (ITRMF) has a EV-to-EBITDA of -0.98 as of Aug. 11, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Iterum Therapeutics. According to the industry distribution chart, Iterum Therapeutics ranks #999999 out of 402 companies in the Biotechnology industry.
Is Iterum Therapeutics' EV-to-EBITDA too high?
Iterum Therapeutics' current EV-to-EBITDA is -0.98. Based on the distribution chart, Iterum Therapeutics ranks #999999 out of 402 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Iterum Therapeutics' EV-to-EBITDA compare to HEPA and MTNB?
According to the Biotechnology industry distribution chart, Iterum Therapeutics ranks #999999 out of 402 companies for EV-to-EBITDA. This places Iterum Therapeutics in the lower half of its industry. The industry median EV-to-EBITDA is 13.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.30, based on 402 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Iterum Therapeutics. For the Biotechnology industry, the median EV-to-EBITDA is 13.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Iterum Therapeutics's current EV-to-EBITDA is -0.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iterum Therapeutics stock overvalued right now?
Iterum Therapeutics (ITRMF) has a current EV-to-EBITDA of -0.98. The current EV-to-EBITDA is -0.98. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Iterum Therapeutics (ITRMF), the current EV-to-EBITDA is -0.98 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ITRMF has been successfully added to your 
